公开(公告)号：US20020197270A1

公开(公告)日：2002-12-26

申请号：US10032482

申请日：2002-01-02

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irun R. Cohen ,  Varda Rotter ,  Roland Wolkowicz ,  Pedro Ruiz ,  Neta Erez-Alon ,  Johannes Herkel

IPC: A61K048/00 ,  A61K039/00

CPC classification number: C07K16/30 ,  A61K39/00 ,  A61K2039/505 ,  A61K2039/51 ,  C07K16/18 ,  C07K2317/565 ,  C07K2317/73

Abstract: The invention relates to the use of an immunogen selected from the group consisting of (i) an anti-p53 mAb; (ii) a fragment of an anti-p53 mAb; (iii) a peptide based on a CDR of the heavy or light chain of an anti-p53 mAb, which peptide is capable of eliciting antibodies to p53; and (iv) a DNA molecule coding for the variable (V) region of an anti-p53 mAb in a suitable gene delivery vehicle, for the preparation of a pharmaceutical composition useful for induction of anti-tumor immunity in mammals, for activating an enhanced immune response to a p53 molecule in mammals, and/or for induction of immune responses to mutated and wild-type forms of a p53 in mammals. The use of anti-p53 mAbs and novel peptides based on the CDR2 and CDR3 of the heavy chains and CDR3 of the light chains of different anti-p53 mAbs are disclosed.

Abstract translation: 本发明涉及选自以下的免疫原的用途：（i）抗p53 mAb; （ii）抗p53 mAb的片段; （iii）基于抗p53 mAb的重链或轻链的CDR的肽，该肽能够引发针对p53的抗体; 和（iv）编码合适的基因递送载体中抗p53mAb的可变（V）区的DNA分子，用于制备用于诱导哺乳动物抗肿瘤免疫的药物组合物，用于激活增强的 对哺乳动物中p53分子的免疫应答，和/或用于诱导哺乳动物中突变​​和野生型形式的p53的免疫应答。 公开了使用抗p53 mAb和基于不同抗p53 mAb的轻链的CDR2和CDR3的CDR3和新型肽。